Get the Stockscreener App
35.67
4.24%
-1.58
After Hours:
35.71
0.04
+0.11%
Metsera Inc stock is traded at $35.67, with a volume of 1.61M.
It is down -4.24% in the last 24 hours and up +15.51% over the past month.
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
See More
Previous Close:
$37.25
Open:
$37.44
24h Volume:
1.61M
Relative Volume:
1.32
Market Cap:
$3.75B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.56%
1M Performance:
+15.51%
6M Performance:
+38.36%
1Y Performance:
+0.00%
1-Day Range:
$35.41
$37.55
1-Week Range:
$34.75
$38.45
52-Week Range:
$12.30
$47.40
Metsera Inc Stock (MTSR) Company Profile
Name
Metsera Inc
Sector
Industry
Phone
(212) 784-6595
Address
3 WORLD TRADE CENTER, NEW YORK
Compare MTSR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
35.67 | 3.83B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Initiated | Leerink Partners | Outperform |
| Jun-20-25 | Initiated | Wells Fargo | Overweight |
| Feb-25-25 | Initiated | BofA Securities | Buy |
| Feb-25-25 | Initiated | Evercore ISI | Outperform |
| Feb-25-25 | Initiated | Guggenheim | Buy |
Metsera Inc Stock (MTSR) Latest News
Alliancebernstein L.P. Invests $32.74 Million in Metsera Inc. $MTSR - MarketBeat
Wall Street Zen Downgrades Metsera (NASDAQ:MTSR) to Sell - MarketBeat
Invesco Ltd. Purchases New Position in Metsera Inc. $MTSR - MarketBeat
Metsera (NASDAQ:MTSR) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
Corebridge Financial Inc. Invests $206,000 in Metsera Inc. $MTSR - MarketBeat
Bank of America Securities Raises PT on Metsera (MTSR), Keeps a Buy - MSN
Metsera, Inc. (MTSR)’s MET-233i Shows 8% Weight Loss in Phase 1 - Yahoo Finance
Leerink Partners Initiates Metsera(MTSR.US) With Buy Rating, Announces Target Price $77 - 富途牛牛
Metsera (NASDAQ:MTSR) Coverage Initiated at Leerink Partners - MarketBeat
Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting - GlobeNewswire
Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting - GlobeNewswire Inc.
Metsera, Inc. Poised for Market Outperformance with Innovative Obesity Treatment Platform - TipRanks
MetLife Investment Management LLC Purchases Shares of 9,342 Metsera Inc. $MTSR - MarketBeat
250,000 Shares in Metsera Inc. $MTSR Purchased by Eventide Asset Management LLC - MarketBeat
Cormorant Asset Management LP Acquires Shares of 400,000 Metsera Inc. $MTSR - MarketBeat
20,317 Shares in Metsera Inc. $MTSR Bought by Nuveen LLC - MarketBeat
EcoR1 Capital LLC Takes Position in Metsera Inc. $MTSR - MarketBeat
Metsera: An Emerging Contender In The GLP‑1 Arena (NASDAQ:MTSR) - Seeking Alpha
Why Metsera, Inc. Stock is Climbing Higher - TipRanks
Biopharma IPO activity slows, but 2025 returns are surging - BioWorld MedTech
Leerink Partners initiates coverage on Metsera stock with Outperform rating - Investing.com
Metsera initiated with an Outperform at Leerink - TipRanks
Leerink Initiates Metsera at Outperform With $77 Price Target - MarketScreener
RA Capital Management L.P. Acquires New Shares in Metsera Inc. $MTSR - MarketBeat
Is Metsera Inc. affected by consumer sentimentPortfolio Value Summary & Daily Stock Momentum Reports - beatles.ru
Metsera (NASDAQ:MTSR) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
Can Metsera Inc. ride the EV wave2025 Growth vs Value & Fast Entry High Yield Tips - beatles.ru
Will Metsera Inc. benefit from green energy policiesJuly 2025 Technicals & Intraday High Probability Setup Alerts - beatles.ru
Will a bounce in Metsera Inc. offer an exitBreakout Watch & Risk Adjusted Swing Trade Ideas - Newser
Live market analysis of Metsera Inc.Price Action & AI Forecasted Entry/Exit Points - Newser
Braidwell LP Invests $4.76 Million in Metsera Inc. $MTSR - MarketBeat
Is Metsera Inc. vulnerable to short sellersMarket Rally & Accurate Entry/Exit Alerts - 뉴스영
Can you recover from losses in Metsera Inc.July 2025 Closing Moves & Scalable Portfolio Growth Ideas - Newser
Sector ETF performance correlation with Metsera Inc.Market Performance Recap & Smart Money Movement Alerts - Newser
Should you hold or exit Metsera Inc. nowJuly 2025 Opening Moves & Detailed Earnings Play Strategies - Newser
Charles Schwab Investment Management Inc. Buys New Shares in Metsera Inc. $MTSR - MarketBeat
Paradigm Biocapital Advisors LP Purchases Shares of 1,191,462 Metsera Inc. $MTSR - MarketBeat
Heatmap analysis for Metsera Inc. and competitors2025 Trading Recap & Verified Swing Trading Watchlists - Newser
Can volume confirm reversal in Metsera Inc.2025 Key Highlights & Entry Point Confirmation Alerts - Newser
Short interest data insights for Metsera Inc.2025 Market Overview & Low Risk Growth Stock Ideas - Newser
Sentiment analysis tools applied to Metsera Inc.Market Risk Analysis & Low Risk Investment Opportunities - Newser
FMR LLC sells Metsera (MTSR) shares for $9,648 - Investing.com India
Metsera price target raised to $50 from $45 at BofA - MSN
FMR LLC sells Metsera (MTSR) shares for $9,648 By Investing.com - Investing.com Australia
What are analysts’ price targets for Metsera Inc.2025 Price Action Summary & Daily Stock Trend Watchlist - خودرو بانک
Analyzing drawdowns of Metsera Inc. with statistical tools2025 Key Highlights & Technical Pattern Alert System - Newser
Is Metsera Inc. trending in predictive chart models2025 Key Highlights & High Return Stock Watch Alerts - Newser
Will Metsera Inc. see short term momentum2025 Dividend Review & Community Consensus Trade Signals - Newser
Metsera to Present at Upcoming September Investor Conferences - 富途牛牛
Brokerages Set Metsera Inc. (NASDAQ:MTSR) PT at $59.00 - MarketBeat
Can Metsera Inc. stock double in the next yearWeekly Market Outlook & High Win Rate Trade Alerts - خودرو بانک
Metsera Inc Stock (MTSR) Financials Data
There is no financial data for Metsera Inc (MTSR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):